{'fraction_non_alphanumeric': 0.023574144486692015, 'fraction_numerical': 0.00988593155893536, 'mean_word_length': 4.927927927927928, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Rutin exerts antiulcer effect by inhibiting the gastric proton pump

415 Indian Journal of Pharmacology | August 2013 | Vol 45 | Issue 4 marker of a complete DPD deficiency phenotype. In this light, Johnson et al., reported a profound DPD deficiency case with absent DPD activity and a particularly elevated plasmatic U levels.[3] The result obtained by Johnson et al., was completely consistent with our findings. Moreover, another study showed that the Uracil / dihydrouracil plasmatic ratio could be used as a phenotypic test for the assessment of DPD deficiency,[4] which was also in agreement with our findings. The molecular analysis performed on the patient‘s DPD gene (DPYD) revealed the absence of known pathogenic mutations.[1] Therefore, we looked for some mutations that could be responsible for the deleterious effects on the DPD activity in the studied subjects, but none of these mutations was found. This data demonstrated that the absence of known mutations in some cancer patients and the great number of mutations involved in DPD deficiency could be a limitation for the molecular approaches used as tools to screen for DPD deficiency in cancer patients. The simple and rapid phenotypic approach described in this report could be a reliable method to pre-screen DPD deficiency in cancer patients.